Agilent BioTek Celebrates a Decade of Cell Imaging and Microscopy Innovation Agilent BioTek Celebrates a Decade of Cell Imaging and Microscopy Innovation Agilent Technologies Inc. (NYSE: A)...
Agilent Wins SEAL Award for Innovative Products that Help Customers Achieve Their Sustainability Goals Agilent Wins SEAL Award for Innovative Products that Help Customers Achieve Their Sustainability Goals Agilent...
Agilent Announces Solutions Innovation Research Award to Dr. Jiangbin Ye Agilent Announces Solutions Innovation Research Award to Dr. Jiangbin Ye Agilent Technologies Inc. (NYSE: A) announced...
Agilent Announces End-to-End Digital Pathology Workflow Solution at USCAP 2023 Agilent Announces End-to-End Digital Pathology Workflow Solution at USCAP 2023 Agilent Technologies Inc. (NYSE: A)...
Agilent’s Certified Pre-Owned Instruments Program Receives Environmental Award Agilent’s Certified Pre-Owned Instruments Program Receives Environmental Award Agilent Technologies Inc. (NYSE: A)...
Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell...
Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial Carcinoma (MIUC) Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Muscle-Invasive Urothelial...
Agilent Names John Palma to Lead Global Medical Affairs Organization Agilent Names John Palma to Lead Global Medical Affairs Organization Agilent Technologies, Inc. (NYSE: A) today...
Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric,...
Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast...